Breast cancer is the most common malignant tumor and ranks as the leading cause of cancer-related death among women. Although endocrine and targeted therapy have obtained positive curative effects, the high recurrence rate and mortality associated with drug resistance remain obstacles. Solid evidence indicates that lysophosphatidylcholine acyltransferase 1 (LPCAT1) plays a key role during tumorigenesis. Notably, LPCAT1 upregulates cancer-related Erbb signaling pathways by affecting the lipid microenvironment around the cell membrane. However, its function and mechanism in breast cancer are still elusive. The regulation of long noncoding RNAs (lncRNAs) on multiple molecules is closely related to the occurrence and development of breast cancer. At present, most studies contend that lncRNAs facilitate downstream target gene expression by regulating ceRNAs, while others suggest that lncRNAs may function as upstream modulators, inhibiting gene expression by promoting splicing of per-miRNAs. In this study, the expression and prognosis of LPCAT1 and noncoding RNA (LINC01176) were analyzed in multiple tumors. Data in The Genotype-Tissue Expression (GTEx) indicated that LPCAT1 may be a potential oncogene in breast cancer, while LINC01176, as a new noncoding RNA, may have an inhibitory effect on breast cancer. A series of bioinformatic analyses, including expression, correlation, and prognostic analyses, confirmed that the expression of LPCAT1 is related to the regulation of the noncoding RNA (lncRNA) LINC01176. Finally, the LINC01176/hsa-miR-218-5p/LPCAT1 axis was identified as the most likely upstream lncRNA-related pathway for LPCAT1 in breast cancer. Mechanistically, we found that LPCAT1, LINC01176, and hsa-miR-218-5p are related to various tumor-related signaling pathways by KEGG enrichment analysis, including the Erbb signaling pathway, which is closely related to breast cancer, and tumor angiogenesis-related VEGF and Notch signaling pathways. Moreover, the LPCAT1 level was significantly positively associated with HER2, PC, VEGF, and NOTCH, while LINC was significantly negatively associated with HER2, PC, and NOTCH. In summary, our study suggests that LPCAT1 contributes to poor prognosis in breast cancer and that we can improve the prognosis of breast cancer by regulating the LINC01176/hsa-miR-218-5p/LPCAT1 axis.